

Interview Summary	Applicant(s)	Applicant(s)	
	10/043,452	BROZE, GEORGE J.	
	Examiner	Art Unit	
	Maryam Monshipouri	1652	

All participants (applicant, applicant's representative, PTO personnel):

(1) Maryam Monshipouri. (3) _____.

(2) Mr. Scott J. Meyer. (4) _____.

Date of Interview: 27 October 2003.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.
If Yes, brief description: _____.

Claim(s) discussed: 7 and 11.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: It was pointed out that claims 7 and 11 of this application are anticipated by claims 1-2 in U.S. patent No. 6,265,378. The examiner requested that applicant files a terminal disclaimer to overcome the obviousness type double patenting issues. Mr. Meyer agreed with the examiner and promised to file a terminal disclaimer shortly.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.


MARYAM MONSHIPOURI, PH.D.
PRIMARY EXAMINER

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Art Unit: 1652

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Mr. Scott J. Meyer, on October 27th, 2003.

Examiner's Amendment to the Claims

Cancel claims 8, and 12..

In claim 7, line 2, after "patient a", insert --- ZPI ---.

In claim 7, lines 2-3, after "coagulation inhibitor", delete " selected from the group consisting of Protein Z and ZPI".

In claim 11, after " in which the", insert --- ZPI ---.

In claim 11, after " coagulation inhibitor", delete " is ZPI" and substitute therefor --- has an amino acid sequence corresponding to residues 1-423 of SEQ ID NO:8 ---.

Examiner's Amendments to the Specification

In page 1, underneath the title delete " This is a division of application Ser. No. 09/696,364, filed October 25, 2000, which is a division of application Ser. No. 09/271,608, filed March 17, 1999, which is a continuation-in-part of provisional application Ser. No. 60/086,571, filed May 19, 1998 " and substitute therefor --- This is a division of U.S. application number

Art Unit: 1652

09/696,364, filed 10/25/2000, now U.S. Patent No. 6369031, which is divisional of U.S. application number 09/271,608 filed 3/17/1999, now U.S. Patent No. 6245741, which claims priority to Provisional application 60/086,571, filed 5/19/1998, now abandoned. ---.

The following is an **Examiner's Statement of Reasons for Allowance**:

Claims 7 and 11 are directed to a method of inhibiting blood coagulation in a patient in need thereof comprising administering to said patient a ZPI coagulation inhibitor of specific amino acid sequence.

Claimed ZPI coagulation inhibitor is free of prior art. Further, the prior art does not suggest such specifically claimed product. Hence, said ZPI is also non-obvious. Since ZPI is both novel and non-obvious, its claimed method of use is also novel and non-obvious.

Claims 7 and 11 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Maryam Monshipouri, Ph.D. whose telephone number is (703) 308-1083. The Examiner can normally be reached daily from 8:30 A.M. to 4:30 P.M.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Dr. P. Achutamurthy, can be reached at (703) 308-3804. The OFFICIAL fax number for Technology Center 1600 is (703) 308-4242.

Application/Control Number: 10/043,452

Page 4

Art Unit: 1652

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Ref: 10/043,452
MARYAM MONSHIPOURI, PH.D.
PRIMARY EXAMINER